ALSO NOTED: Novartis sued over withdrawn child cold meds; Teva to expand, hire in Czech Republic;

In what could be a harbinger of more lawsuits over the OTC cold meds for children that FDA warned against and companies withdrew last fall, a California mother sued Novartis over its Triaminic cough-and-cold products. Report

Teva Pharmaceuticals' Ivax unit plans to spend $60.7 million to expand its plant in the Czech Republic, planning to add 400 workers there and amp up production threefold. Report

Sciele Pharma announced it would buy several products from Verus Pharmaceuticals for $29 million, including the emergency allergy shot Twinject. Report

Isis Pharmaceuticals reported a fourth-quarter loss of $7 million on revenues of $24.7 million, falling short of analyst estimates. Report

For the first time, federal authorities are conceding a link between vaccines and autistic symptoms--just not the link activists thought. Report

The venture capital group Perseus has pumped $10 million dollars into NanoBio, bringing its total investment in the University of Michigan spin-off to $30 million. Report

Amgen got some much-needed good news yesterday after an FDA panel endorsed the approval of Nplate, its drug for a rare blood disorder. Report

Genentech CEO Arthur Levinson (photo) scooped up close to $14 million in compensation last year, even as its stock price slid in the face of slowing cancer therapy revenues. Report

Most popular this week: Pfizer's Kindler can't quash mega-deal talk. Report

And Finally... Could public funding make drug R&D more efficient? Report

Suggested Articles

Pfizer’s Ibrance has met with success in breast cancer since breaking onto the scene in 2015. But its first foray into early breast cancer was a bust.

After years of having first-line liver cancer market to itself, Bayer’s Nexavar is getting major competition from Roche's Tecentriq.

Most of the recent enthusiasm around AbbVie’s new drugs has centered on Skyrizi and Rinvoq, but elagolix wants a piece of the spotlight, too.